Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
13.9.2021 16:00:00 EEST | Business Wire | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) , a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced detailed data from a Phase 2 study of KHK4083/AMG 451 will be highlighted in late-breaking oral presentation at the European Academy of Dermatology and Venereology 30th Virtual Congress to be held September 29 – October 2, 2021. KHK4083/AMG 451 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.
Presentation Title:
Efficacy and safety results of KHK4083/AMG 451 (anti-OX40 mAb) in subjects with moderate to severe atopic dermatitis: a phase 2, multicentre, randomized, double-blind, parallel-group, placebo-controlled study
Submission Topic: 5. Atopic Dermatitis/Eczema
Session date and time: Saturday 2 October 2021, 10.00 - 11.00(CEST)
Primary Author: Emma Guttman-Yassky, M.D./Ph.D., System Chair for the Department of Dermatology and Waldman Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai and Director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at Mount Sinai.
The abstract will be available on the EADV Congress website.
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
About KHK4083/AMG 451
KHK4083/AMG 451 is an anti-OX40 fully human monoclonal antibody engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity. The initial KHK4083/AMG 451 antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.
KHK4083/AMG 451 targets and inhibits the activity of the OX40 receptor expressed on the surface of effector T-cells, and has been shown to deplete activated OX40+ T-cells by ADCC. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in their development. Kyowa Kirin antibodies powered by POTELLIGENT technology with ADCC activity are currently marketed in several other therapeutic areas, including Oncology and Asthma. This potent antibody-enhancement platform is also licensed to numerous third parties throughout the biopharmaceutical industry.
On June 1, 2021, Kyowa Kirin entered into an agreement with Amgen (NASDAQ: AMGN) to jointly develop and commercialize KHK4083/AMG 451. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-commercialize the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia.
An overview of the KHK4083/AMG 451 Phase 2 Study
A Phase 2, multicenter, randomized, double-blind, and placebo-controlled clinical study (NCT03703102) was conducted in the U.S., Japan, Canada, and Germany to investigate the efficacy and safety of KHK4083/AMG 451. The study included 274 patients with moderate-to-severe atopic dermatitis, who were not adequately controlled with topical agents. The primary endpoint of the study was "percent change from baseline in Eczema Area and Severity Index (EASI) 1 at 16 weeks”.
About OX40
OX40 is a co-stimulatory molecule and a member of the tumor necrosis factor receptor (TNFR) superfamily. It has been reported that activated effector T cells express OX402,3 and are present in the lesions of patients with atopic dermatitis4. Professor Michael Croft, Ph.D., who is Director, Scientific Affairs, La Jolla Institute for Immunology helped identify that OX40 plays an important role in T cell proliferation, survival and formation of memory T cells5.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
References
- Hanifin JM.; Thurston M.; Omoto M.; Cherill R.; Tofte SJ.; Graeber M: The eczema area and severity index（EAS）: assessment of reliability in atopic dermatitis. EASI Evaluator Group: Exp Dermatol, 2001; 10: 11-18.
- Croft, M.; So, T.; Duan, W.; Soroosh, P.: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol: Rev. 2009, 229, 173–191.
- Croft, M. Control of Immunity by the TNFR-Related Molecule OX40 (CD134): Annu. Rev. Immunol. 2010, 28, 57–78.
- Masutaka F.; Mihoko F. OX40L–OX40 Signaling in Atopic Dermatitis: J. Clin. Med. 2021, 10, 2578
- Gramaglia I; Jember A; Pippig SD; Weinberg AD, Killeen N; Croft M: The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion: J Immunol 2000: 165 (6) 3043-50; DOI: 10.4049/jimmunol.165.6.3043
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005356/en/
Contact information
Hiroki Nakamura (Global, Japan), +81-3-5205-7205
Lauren Walrath (North America), +1-646-526-4454
Stacey Minton (EMEA), +44 (0) 7769 65607
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carbon Measures Opens Singapore Office and Launches First In-Country Pilot to Advance Industrial Decarbonization in Hard-to-Abate Sectors12.11.2026 13:00:00 EET | Press release
Today, at COP31, Carbon Measures announced the establishment of its Singapore office, with support from the Singapore Economic Development Board (EDB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112827071/en/ Carbon Measures opens Singapore office and launches first in-country pilot to advance industrial decarbonization in hard-to-abate sectors. The Singapore office will serve as Carbon Measures’ Asia-Pacific hub, expanding its technical expertise and knowledge capabilities while strengthening engagement with key stakeholders across the region. The office will focus on advancing industrial decarbonization policies for hard-to-abate sectors, convening companies, nonprofit organizations, academic institutions and other partners to guide the Pilot’s development and implementation. “We welcome Carbon Measures’ establishment of its first office in the region. By piloting new approaches for product-level carbon accounting,
Focused Support Delivers Link 16 to Royal Netherlands Air and Space Force MQ-9 Fleet With Cavok STRIKE12.11.2026 13:00:00 EET | Press release
Focused Support LLC today announced the successful deployment of Cavok® STRIKE to the Royal Netherlands Air and Space Force (RNLASF), providing its MQ-9 fleet with enhanced Link 16 participation capabilities without requiring modifications to the aircraft. The deployment represents a significant advance in integrating remotely piloted aircraft into the shared tactical picture, improving situational awareness, interoperability, and coordination across joint and coalition forces. The installation marks a key milestone for Focused Support as Cavok STRIKE expands into European military operations. Integrated within the Cavok Mission Ecosystem, STRIKE addresses a persistent tactical challenge: extending Link 16 to non-traditional participants without costly or complex aircraft modifications. Focused Support Founder and CEO, Jonathan Shill, remarked, “Two decades ago we asked for Link 16 on the MQ-1 Predator but were denied because the 8 lb. terminal represented a half hour of time on statio
Ahead of Frieze Abu Dhabi, 421 Arts Campus Spotlights Emerging Artistic Practices12.11.2026 12:15:00 EET | Press release
As Abu Dhabi prepares to welcome the international art community for the inaugural Frieze Abu Dhabi this November, 421 Arts Campus presents two exhibitions highlighting artistic experimentation, research, and emerging creative practices in the UAE and wider region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112518634/en/ Juma Alhaj, Revelation, 2026 at 421 Arts Campus. Courtesy of 421 and the artist. (Photography by: Ismail Noor, Seeing Things) On view until 10 January 2027, the exhibitions bring together distinct artistic approaches, from Juma Alhaj’s exploration of reflection and self-discovery to an examination of how knowledge is formed and shared through informal modes of communication. Revelation, the first institutional solo exhibition by Emirati artist Juma Alhaj, marks a significant evolution in his practice. Grounded in reading, journaling, and philosophical inquiry, the exhibition explores reflection, solit
a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT12.11.2026 10:00:00 EET | Press release
a2z Radiology AI Inc. today announced that a2z-Drafter has been certified under the EU Medical Device Regulation (MDR). The software supports triage, detection and report drafting on CT scans of the head, chest, abdomen and/or pelvis. “Radiology teams have had to piece together separate AI tools for each condition and body region,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Drafter is one product that works on head, chest and abdomen-pelvis CT scans and gives the radiologist a structured starting point for the report. This certification lets us bring that to radiology teams in the European Union.” a2z-Drafter detects 182 validated radiological findings on CT studies of the head, chest, abdomen and/or pelvis, with supplementary attributes for selected findings. The findings span acute conditions such as subarachnoid hemorrhage, midline shift, pneumothorax and bowel obstruction, findings that need prompt workup such as obstructing ureteral stones and aortic aneury
KiddeFenwal Secures A2P System Certification from Centre National de Prévention et de Protection in France12.11.2026 10:00:00 EET | Press release
KiddeFenwal, the global leader in fire protection and safety controls, has received an Assurance Prévention Protection (A2P) System Certification for its NATURA™ inert gas fire suppression system. The designation from France’s Centre National de Prévention et de Protection (CNPP), one of the most respected fire safety testing and certification organizations in Europe, illustrates how KiddeFenwal is expanding the reach of its industry-leading technologies throughout the world with the support of independent, third-party evaluators. “KiddeFenwal is grateful to CNPP for standing behind our proven NATURA™ system,” said Rekha Agrawal, CEO of KiddeFenwal. “The certification enables our systems to protect the facilities and institutions that matter most, such as data centers, battery energy storage systems and power generation applications. This will lead to stronger protections all throughout France.” Since its launch in 2019, KiddeFenwal’s NATURA™ has offered facilities an enhanced means of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom